NEW YORK (GenomeWeb) – Ambry Genetics said this week that it is adding a new feature to its hereditary cancer risk testing menu: a service called +RNAinsight, which adds RNA sequencing of a group of target genes to the company's existing DNA sequencing panel.
The new offering doesn’t change the cost or turnaround time, which is the same as for the company’s DNA-only testing, said Brigette Davis, Ambry's senior VPt of research and development .
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
